Ann W. Silk, MD, discusses preliminary results of the CAPRA trial, a phase 1B study of intratumoral coxsackievirus A21 (CVA21; CAVATAK) and systemic pembrolizumab in patients with advanced melanoma.
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More